{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:37:41Z","timestamp":1791916661082,"version":"4.3.4"},"reference-count":74,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Adult T-cell leukemia-lymphoma (ATL) is an aggressive mature T-cell malignancy that arises in approximately 5% of carriers of human T-lymphotropic virus type 1 (HTLV-1), but this risk is not random among carriers. We describe recent advance in pathogenesis, risk factors and for early detection of ATL.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Unraveling ATL molecular genetics has shed light on pathogenesis and provides insights into novel therapeutic targets. Moreover, an important step in improving outcomes is identifying asymptomatic carriers who are at high risk of progression to ATL, which has traditionally relied on quantifying the proviral load (PVL). This can be done by quantifying oligoclonality- and in particular the expanded clone- with molecular and flow cytometric techniques, that can be applied to a clinical setting. Studies using these methods have shown that carriers with oligoclonal populations are at an increased risk of transformation, beyond that that predicted by PVL alone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>There is an urgent unmet need for developing novel therapies in ATL in order to improve survival. Recent advances in the molecular and epigenetic landscape of ATL, and the early detection of disease offer the potential to intervene early, before disease becomes aggressive, and to offer tailored therapeutic strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000000883","type":"journal-article","created":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T09:00:13Z","timestamp":1658826013000},"page":"446-453","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["HTLV-1-related adult T-cell leukemia\/lymphoma: insights in early detection and management"],"prefix":"10.1097","volume":"34","author":[{"given":"Sonia","family":"Wolf","sequence":"first","affiliation":[{"name":"Section of virology, Department of Infectious Diseases, Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Vercruyssen","sequence":"additional","affiliation":[{"name":"Department for Haematology, Jules Bordet Institute, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Cook","sequence":"additional","affiliation":[{"name":"Centre for Haematology, Imperial College London"},{"name":"National Centre for Human Retrovirology, Imperial College Healthcare NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,7,25]]},"reference":[{"key":"R1-20250526","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.V50.3.481.481","article-title":"Adult T-cell leukemia: clinical and hematologic features of 16 cases","volume":"50","author":"Uchiyama","year":"1977","journal-title":"Blood"},{"key":"R2-20250526","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R3-20250526","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1073\/pnas.81.8.2534","article-title":"Monoclonal integration of human T-cell leukemia provirus in all primary tumors of adult T-cell leukemia suggests causative role of human T-cell leukemia virus in the disease","volume":"81","author":"Yoshida","year":"1984","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R4-20250526","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3389\/fmicb.2012.00388","article-title":"Epidemiological aspects and world distribution of HTLV-1 infection","volume":"3","author":"Gessain","year":"2012","journal-title":"Front Microbiol"},{"key":"R5-20250526","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.tracli.2015.12.001","article-title":"Infection with human T-lymphotropic virus types-1 and -2 (HTLV-1 and -2): implications for blood transfusion safety","volume":"23","author":"Murphy","year":"2016","journal-title":"Transfus Clin Biol"},{"key":"R6-20250526","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1159\/000168722","article-title":"Adult T-cell leukemia\/lymphoma in a renal transplant recipient: an opportunistic occurrence","volume":"14","author":"Williams","year":"1994","journal-title":"Am J Nephrol"},{"key":"R7-20250526","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood-2009-12-257410","article-title":"Human T-cell leukemia virus type I (HTLV-1) proviral load and disease progression in asymptomatic HTLV-1 carriers: a nationwide prospective study in Japan","volume":"116","author":"Iwanaga","year":"2010","journal-title":"Blood"},{"key":"R8-20250526","first-page":"302","article-title":"HTLV-I serostatus of mothers of patients with adult T-cell leukemia and HTLV-I-associated myelopathy\/tropical spastic paraparesis","volume":"1","author":"Bartholomew","year":"1998","journal-title":"J Hum Virol"},{"key":"R9-20250526","doi-asserted-by":"crossref","first-page":"ofv032","DOI":"10.1093\/ofid\/ofv032","article-title":"Adult T-cell leukemia\/lymphoma in a caucasian patient after sexual transmission of human T-cell lymphotropic virus type 1","volume":"2","author":"Sibon","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"R10-20250526","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/hon.2900040105","article-title":"Familial disposition of adult T-cell leukemia and lymphoma","volume":"4","author":"Ichimaru","year":"1986","journal-title":"Hematol Oncol"},{"key":"R11-20250526","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s10552-016-0784-8","article-title":"Smoking is a risk factor for development of adult T-cell leukemia\/lymphoma in Japanese human T-cell leukemia virus type-1 carriers","volume":"27","author":"Kondo","year":"2016","journal-title":"Cancer Causes Control"},{"key":"R12-20250526","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1182\/blood-2015-03-632489","article-title":"Treatment and survival among 1594 patients with ATL","volume":"126","author":"Katsuya","year":"2015","journal-title":"Blood"},{"key":"R13-20250526","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1111\/cas.13398","article-title":"Epidemiological and clinical features of adult T-cell leukemia-lymphoma in Japan, 2010-2011: a nationwide survey","volume":"108","author":"Nosaka","year":"2017","journal-title":"Cancer Sci"},{"key":"R14-20250526","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1200\/JCO.2011.35.5578","article-title":"Use of zidovudine and interferon alfa with chemotherapy improves survival in both acute and lymphoma subtypes of adult T-cell leukemia\/lymphoma","volume":"29","author":"Hodson","year":"2011","journal-title":"J Clin Oncol"},{"key":"R15-20250526","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1002\/cncr.32556","article-title":"Epidemiology and survival trend of adult T-cell leukemia\/lymphoma in the United States","volume":"126","author":"Shah","year":"2019","journal-title":"Cancer"},{"key":"R16-20250526","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.3389\/fmicb.2020.01124","article-title":"Epidemiology of HTLV-1 infection and ATL in Japan: an update","volume":"11","author":"Iwanaga","year":"2020","journal-title":"Frontiers in microbiology"},{"key":"R17-20250526","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1365-2141.1991.tb08051.x","article-title":"Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87)","volume":"79","author":"Shimoyama","year":"1991","journal-title":"Br J Haematol"},{"key":"R18-20250526","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/1346-8138.12374","article-title":"Meeting report on the possible proposal of an extranodal primary cutaneous variant in the lymphoma type of adult T-cell leukemia-lymphoma","volume":"41","author":"Tsukasaki","year":"2014","journal-title":"J Dermatol"},{"key":"R19-20250526","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3324\/haematol.2012.069476","article-title":"Premorbid human T-lymphotropic virus type I proviral load, rather than percentage of abnormal lymphocytes, is associated with an increased risk of aggressive adult T-cell leukemia\/lymphoma","volume":"98","author":"Hodson","year":"2013","journal-title":"Haematologica"},{"key":"R20-20250526","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0145-2126(92)90168-7","article-title":"Phenotypic diversity and prognosis of adult T-cell leukemia","volume":"16","author":"Kamihira","year":"1992","journal-title":"Leuk Res"},{"key":"R21-20250526","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1182\/blood.2019004045","article-title":"How I treat adult T-cell leukemia\/lymphoma","volume":"137","author":"Cook","year":"2021","journal-title":"Blood"},{"key":"R22-20250526","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1200\/JCO.2008.18.2428","article-title":"Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting","volume":"27","author":"Tsukasaki","year":"2009","journal-title":"J Clin Oncol"},{"key":"R23-20250526","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/ng.3415","article-title":"Integrated molecular analysis of adult T cell leukemia\/lymphoma","volume":"47","author":"Kataoka","year":"2015","journal-title":"Nat Genet"},{"key":"R24-20250526","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1182\/blood-2015-06-644948","article-title":"Variegated RHOA mutations in adult T-cell leukemia\/lymphoma","volume":"127","author":"Nagata","year":"2016","journal-title":"Blood"},{"key":"R25-20250526","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41375-020-0900-3","article-title":"Targeted deep sequencing reveals clonal and subclonal mutational signatures in Adult T-cell leukemia\/lymphoma and defines an unfavorable indolent subtype","volume":"35","author":"Mar\u00e7ais","year":"2020","journal-title":"Leukemia"},{"key":"R26-20250526","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-01-824607","article-title":"North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies","volume":"132","author":"Shah","year":"2018","journal-title":"Blood"},{"key":"R27-20250526","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1182\/blood.2019001815","article-title":"Genomic landscape of young ATLL patients identifies frequent targetable CD28 fusions","volume":"135","author":"Yoshida","year":"2020","journal-title":"Blood"},{"key":"R28-20250526","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1182\/blood.2021013568","article-title":"Whole-genome landscape of adult T-cell leukemia\/lymphoma","volume":"139","author":"Kogure","year":"2021","journal-title":"Blood"},{"key":"R29-20250526","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1182\/blood.V66.1.120.120","article-title":"Preleukemic state of adult T cell leukemia: abnormal T lymphocytosis induced by human adult T cell leukemia-lymphoma virus","volume":"66","author":"Kinoshita","year":"1985","journal-title":"Blood"},{"key":"R30-20250526","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1182\/blood.V80.4.1012.1012","article-title":"Frequent clonal proliferation of human T-cell leukemia virus type 1 (HTLV-1)-infected T cells in HTLV-1-associated myelopathy (HAM-TSP)","volume":"80","author":"Furukawa","year":"1992","journal-title":"Blood"},{"key":"R31-20250526","first-page":"4862","article-title":"Persistent clonal proliferation of human T-lymphotropic virus type I-infected cells in vivo","volume":"57","author":"Etoh","year":"1997","journal-title":"Cancer Res"},{"key":"R32-20250526","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/ana.410260304","article-title":"Increased replication of HTLV-I in HTLV-I\u2013associated myelopathy","volume":"26","author":"Yoshida","year":"1989","journal-title":"Ann Neurol"},{"key":"R33-20250526","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1182\/blood-2004-06-2489","article-title":"Natural course of HTLV-1 carriers with monoclonal proliferation of T lymphocytes (\u2019pre-ATL\u2019) in a 20-year follow-up study","volume":"105","author":"Imaizumi","year":"2005","journal-title":"Blood"},{"key":"R34-20250526","doi-asserted-by":"crossref","first-page":"3488","DOI":"10.1182\/blood-2012-07-445593","article-title":"HTLV-1-infected T cells contain a single integrated provirus in natural infection","volume":"120","author":"Cook","year":"2012","journal-title":"Blood"},{"key":"R35-20250526","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1182\/blood-2010-10-312926","article-title":"The host genomic environment of the provirus determines the abundance of HTLV-1-infected T-cell clones","volume":"117","author":"Gillet","year":"2011","journal-title":"Blood"},{"key":"R36-20250526","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1182\/bloodadvances.2017005900","article-title":"Clonality of HTLV-1-infected T cells as a risk indicator for development and progression of adult T-cell leukemia","volume":"1","author":"Firouzi","year":"2017","journal-title":"Blood Adv"},{"key":"R37-20250526","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1038\/leu.2011.379","article-title":"Clinical significance of CADM1\/TSLC1\/IgSF4 expression in adult T-cell leukemia\/lymphoma","volume":"26","author":"Nakahata","year":"2012","journal-title":"Leukemia"},{"key":"R38-20250526","doi-asserted-by":"crossref","first-page":"e1005560","DOI":"10.1371\/journal.ppat.1005560","article-title":"CADM1\/TSLC1 identifies HTLV-1-infected cells and determines their susceptibility to CTL-mediated lysis","volume":"12","author":"Manivannan","year":"2016","journal-title":"PLoS Pathog"},{"key":"R39-20250526","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.V73.6.1664.1664","article-title":"Profiles of expression of activated cell antigens on peripheral blood and lymph node cells from different clinical stages of adult T-cell leukemia","volume":"73","author":"Shirono","year":"1989","journal-title":"Blood"},{"key":"R41-20250526","doi-asserted-by":"crossref","first-page":"e53728","DOI":"10.1371\/journal.pone.0053728","article-title":"The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I","volume":"8","author":"Kobayashi","year":"2013","journal-title":"PLoS One"},{"key":"R42-20250526","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/cas.12639","article-title":"Advanced human T-cell leukemia virus type 1 carriers and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry","volume":"106","author":"Kobayashi","year":"2015","journal-title":"Cancer Sci"},{"key":"R43-20250526","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1023\/A:1027318530127","article-title":"CD4+CD7\u2212 T Cells: a separate subpopulation of memory T cells?","volume":"17","author":"Reinhold","year":"1997","journal-title":"J Clin Immunol"},{"key":"R44-20250526","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/jcp.27099","article-title":"The clinical importance of CD4+CD7\u2212 in human diseases","volume":"234","author":"Haftcheshmeh","year":"2019","journal-title":"J Cell Physiol"},{"key":"R45-20250526","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1097-0320(20000801)40:4<336::AID-CYTO9>3.0.CO;2-0","article-title":"Flow cytometric analysis of the V\u03b2 repertoire in healthy controls","volume":"40","author":"van den Beemd","year":"2000","journal-title":"Cytometry"},{"key":"R46-20250526","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1309\/3A32DTVMH640M2QA","article-title":"Flow cytometric assessment of TCR-V\u03b2 expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional t-cell immunophenotyping and molecular genetic techniques","volume":"121","author":"Morice","year":"2004","journal-title":"Am J Clin Pathol"},{"key":"R47-20250526","doi-asserted-by":"crossref","first-page":"e1006030","DOI":"10.1371\/journal.ppat.1006030","article-title":"T cell receptor vbeta staining identifies the malignant clone in adult t cell leukemia and reveals killing of leukemia cells by autologous CD8+ T cells","volume":"12","author":"Rowan","year":"2016","journal-title":"PLoS Pathog"},{"key":"R48-20250526","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41408-021-00458-8","article-title":"Quantification of T cell clonality in human T cell leukaemia virus type-1 carriers can detect the development of adult T cell leukaemia early","volume":"11","author":"Wolf","year":"2021","journal-title":"Blood Cancer J"},{"key":"R49-20250526","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.3324\/haematol.2019.219253","article-title":"Molecular remissions are observed in chronic adult T-cell leukemia\/lymphoma in patients treated with mogamulizumab","volume":"104","author":"Cook","year":"2019","journal-title":"Haematologica"},{"key":"R50-20250526","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1182\/blood-2009-09-242347","article-title":"Long-term study of indolent adult T-cell leukemia-lymphoma","volume":"115","author":"Takasaki","year":"2010","journal-title":"Blood"},{"key":"R51-20250526","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1200\/JCO.18.00501","article-title":"Revised adult t-cell leukemia-lymphoma International Consensus Meeting Report","volume":"37","author":"Cook","year":"2019","journal-title":"J Clin Oncol"},{"key":"R52-20250526","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1002\/1097-0142(19900115)65:2<327::AID-CNCR2820650224>3.0.CO;2-W","article-title":"Central nervous system involvement in adult T-cell leukemia\/lymphoma","volume":"65","author":"Teshima","year":"1990","journal-title":"Cancer"},{"key":"R53-20250526","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0145-2126(93)90061-O","article-title":"Characteristics of chemotherapy-induced clinical remission in long survivors with aggressive adult T-cell leukemia\/lymphoma","volume":"17","author":"Tsukasaki","year":"1993","journal-title":"Leuk Res"},{"key":"R54-20250526","doi-asserted-by":"crossref","first-page":"4177","DOI":"10.1200\/JCO.2010.28.0669","article-title":"Meta-analysis on the use of zidovudine and interferon-alfa in adult T-cell leukemia\/lymphoma showing improved survival in the leukemic subtypes","volume":"28","author":"Bazarbachi","year":"2010","journal-title":"J Clin Oncol"},{"key":"R55-20250526","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s00277-021-04622-9","article-title":"Poor outcome and high prevalence of invasive fungal infections in patients with adult T-cell leukemia\/lymphoma exposed to zidovudine and interferon alfa","volume":"100","author":"Guery","year":"2021","journal-title":"Ann Hematol"},{"key":"R56-20250526","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12185-014-1665-0","article-title":"Treatment outcome of elderly patients with aggressive adult T cell leukemia-lymphoma: Nagasaki University Hospital experience","volume":"100","author":"Makiyama","year":"2014","journal-title":"Int J Hematol"},{"key":"R57-20250526","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/sj.bmt.1702731","article-title":"Improved outcome of adult T cell leukemia\/lymphoma with allogeneic hematopoietic stem cell transplantation","volume":"27","author":"Utsunomiya","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"R58-20250526","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1038\/sj.leu.2403682","article-title":"Allogeneic hematopoietic stem cell transplantation provides sustained long-term survival for patients with adult T-cell leukemia\/lymphoma","volume":"19","author":"Fukushima","year":"2005","journal-title":"Leukemia"},{"key":"R59-20250526","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1532\/IJH97.07070","article-title":"Allogeneic stem cell transplantation for adult T-cell leukemia\/lymphoma","volume":"86","author":"Okamura","year":"2007","journal-title":"Int J Hematol"},{"key":"R60-20250526","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1182\/blood-2009-10-247510","article-title":"Transplantation of allogeneic hematopoietic stem cells for adult T-cell leukemia: a nationwide retrospective study","volume":"116","author":"Hishizawa","year":"2010","journal-title":"Blood"},{"key":"R61-20250526","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1038\/bmt.2014.143","article-title":"Outcome of patients with HTLV-1-associated adult T-cell leukemia\/lymphoma after SCT: a retrospective study by the EBMT LWP","volume":"49","author":"Bazarbachi","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"R62-20250526","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2015.265","article-title":"Early application of related SCT might improve clinical outcome in adult T-cell leukemia\/lymphoma","volume":"51","author":"Fuji","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"R63-20250526","doi-asserted-by":"crossref","first-page":"928.e1- L 928.e7","DOI":"10.1016\/j.jtct.2021.07.010","article-title":"A Phase I\/II multicenter trial of HLA-haploidentical PBSCT with PTCy for aggressive adult T cell leukemia\/lymphoma","volume":"27","author":"Tanaka","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"R64-20250526","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1200\/JCO.2009.25.3575","article-title":"Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma","volume":"28","author":"Yamamoto","year":"2010","journal-title":"J Clin Oncol"},{"key":"R65-20250526","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1200\/JCO.2011.37.3472","article-title":"Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study","volume":"30","author":"Ishida","year":"2012","journal-title":"J Clin Oncol"},{"key":"R66-20250526","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3324\/haematol.2018.205096","article-title":"Mogamulizumab versus investigator choice of chemotherapy regimen in relapsed\/refractory adult T-cell leukemia\/lymphoma","volume":"104","author":"Phillips","year":"2018","journal-title":"Haematologica"},{"key":"R67-20250526","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/bjh.13338","article-title":"Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: a randomized phase II study","volume":"169","author":"Ishida","year":"2015","journal-title":"Br J Haematol"},{"key":"R68-20250526","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1182\/blood-2018-02-835991","article-title":"CCR4 mutations associated with superior outcome of adult T-cell leukemia\/lymphoma under mogamulizumab treatment","volume":"132","author":"Sakamoto","year":"2018","journal-title":"Blood"},{"key":"R69-20250526","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1200\/JCO.2016.67.8250","article-title":"Pretransplantation anti-CCR4 antibody mogamulizumab against adult T-cell leukemia\/lymphoma is associated with significantly increased risks of severe and corticosteroid-refractory graft-versus-host disease, nonrelapse mortality, and overall mortality","volume":"34","author":"Fuji","year":"2016","journal-title":"J Clin Oncol"},{"key":"R70-20250526","doi-asserted-by":"crossref","first-page":"e107","DOI":"10.1016\/S2352-3026(15)00284-7","article-title":"Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study","volume":"3","author":"Ogura","year":"2016","journal-title":"Lancet Haematol"},{"key":"R71-20250526","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12977-020-0513-y","article-title":"Arsenic trioxide (As2O3) as a maintenance therapy for adult T cell leukemia\/lymphoma","volume":"17","author":"Mar\u00e7ais","year":"2020","journal-title":"Retrovirology"},{"key":"R72-20250526","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1056\/NEJMc1803181","article-title":"Rapid progression of adult T-cell leukemia-lymphoma after PD-1 inhibitor therapy","volume":"378","author":"Ratner","year":"2018","journal-title":"N Engl J Med"},{"key":"R73-20250526","first-page":"696","article-title":"PD-1 inhibitor therapy in adult T-cell leukemia-lymphoma","volume":"379","author":"Ishitsuka","year":"2018","journal-title":"N Engl J Med"},{"key":"R74-20250526","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","article-title":"Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial","volume":"393","author":"Horwitz","year":"2019","journal-title":"Lancet"},{"key":"R75-20250526","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1182\/blood-2021-146657","article-title":"Pivotal Phase 2 study of the EZH1 and EZH2 inhibitor valemetostat tosylate (DS-3201b) in patients with relapsed or refractory adult T-cell leukemia\/lymphoma","volume":"138","author":"Yoshimitsu","year":"2021","journal-title":"Blood"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000883","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T23:09:51Z","timestamp":1748300991000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000000883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,25]]},"references-count":74,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000883","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,25]]}}}